利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

351 条记录 (耗时 0.075 秒)

    Polyol-based polymers
    84.
    发明授权
    Polyol-based polymers 有权
    多元醇类聚合物

    公开(公告)号：US08912304B2

    公开(公告)日：2014-12-16

    申请号：US12600596

    申请日：2008-05-16

    申请人： Joost P. Bruggeman ,  Christiaan Nijst ,  Daniel S. Kohane ,  Robert S. Langer

    发明人： Joost P. Bruggeman ,  Christiaan Nijst ,  Daniel S. Kohane ,  Robert S. Langer

    IPC分类号： C08G63/02 ,  C08G63/668 ,  A61L27/54 ,  A61L27/52 ,  A61L27/58 ,  A61L27/38 ,  A61L27/16 ,  C08G63/21 ,  C08F283/00

    CPC分类号： C08G63/668 ,  A61L27/16 ,  A61L27/38 ,  A61L27/52 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/604 ,  C08G63/21 ,  C08L33/02

    摘要： The present invention provides inventive polyol-based polymers, materials, pharmaceutical compositions, and methods of making and using the inventive polymers and materials. In certain aspects of the invention, an inventive polymer corresponds to a polymer depicted below. Exemplary inventive polymers includes those prepared using polyol units (e.g., xylitol, mannitol, sorbitol, or maltitol) condensed with polycarboxylic acid units (e.g., citric acid, glutaric acid, or sebacic acid). The inventive polymers may be further derivatized or modified. For example, the polymer may be made photocrosslinkable by adding methacrylate moieties to the polymer.

    摘要翻译： 本发明提供本发明的多元醇基聚合物，材料，药物组合物以及制备和使用本发明的聚合物和材料的方法。 在本发明的某些方面，本发明的聚合物对应于下面描述的聚合物。 示例性的本发明聚合物包括使用与多元羧酸单元（例如柠檬酸，戊二酸或癸二酸）缩合的多元醇单元（例如木糖醇，甘露糖醇，山梨糖醇或麦芽糖醇）制备的那些聚合物。 本发明的聚合物可进一步衍生或修饰。 例如，可以通过向聚合物中加入甲基丙烯酸酯部分使聚合物可光交联。

    Polymers for functional particles
    86.
    发明授权
    Polymers for functional particles 有权
    功能颗粒聚合物

    公开(公告)号：US08367113B2

    公开(公告)日：2013-02-05

    申请号：US11803843

    申请日：2007-05-15

    申请人： Frank X. Gu ,  Benjamin A. Teply ,  Robert S. Langer ,  Omid C. Farokhzad

    发明人： Frank X. Gu ,  Benjamin A. Teply ,  Robert S. Langer ,  Omid C. Farokhzad

    IPC分类号： A61K9/14 ,  A61K9/51

    CPC分类号： C08G63/912 ,  A61K9/5153 ,  A61K47/549 ,  A61K47/593 ,  A61K47/60 ,  A61K47/6935 ,  A61K47/6937 ,  A61K49/00 ,  A61K51/1244 ,  B82Y5/00 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/915 ,  Y10T428/2982

    摘要： The present invention generally relates to polymers and macromolecules, in particular, to block polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. The moiety, in some embodiments, may have a molecular weight greater than about 1000 Da; for example, the moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may also be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect of the invention is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other aspects of the invention are directed to methods using such libraries, methods of using or administering such polymeric conjugates, methods of promoting the use of such polymeric conjugates, kits involving such polymeric conjugates, or the like.

    摘要翻译： 本发明一般涉及聚合物和大分子，特别是阻止可用于颗粒如纳米颗粒的聚合物。 本发明的一个方面涉及一种开发具有所需性质的纳米颗粒的方法。 在一组实施方案中，该方法包括制备具有高度控制性质的纳米颗粒的文库，其可通过将两种或多种不同比例的大分子混合在一起形成。 一个或多个大分子可以是部分与生物相容性聚合物的聚合物缀合物。 在一些情况下，纳米颗粒可以含有药物。 在一些实施方案中，该部分可具有大于约1000Da的分子量; 例如，该部分可以包括多肽或多核苷酸，例如适体。 该部分还可以是靶向部分，成像部分，螯合部分，带电部分或治疗部分。 本发明的另一方面涉及制备这种聚合物缀合物的系统和方法。 在一些实施方案中，将含有聚合物的溶液与诸如不混溶液体的液体接触以形成含有聚合物缀合物的纳米颗粒。 本发明的其它方面涉及使用这种文库的方法，使用或施用这种聚合物缀合物的方法，促进使用这种聚合物缀合物的方法，涉及这种聚合物缀合物的试剂盒等。

    HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS
    88.
    发明申请
    HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS 有权
    水凝胶细胞和抗炎药物

    公开(公告)号：US20120213708A1

    公开(公告)日：2012-08-23

    申请号：US13400382

    申请日：2012-02-20

    申请人： Daniel G. Anderson ,  Robert S. Langer ,  Tram T. Dang

    发明人： Daniel G. Anderson ,  Robert S. Langer ,  Tram T. Dang

    IPC分类号： A61K35/12 ,  A61P29/00 ,  A61K49/00 ,  A61K9/00

    CPC分类号： A61K9/1641 ,  A61K9/0019 ,  A61K31/573 ,  A61K35/39 ,  A61K45/06 ,  A61L27/3804 ,  A61L27/48 ,  A61L27/52 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/622 ,  A61L2300/64 ,  C12N5/0676 ,  C12N2502/1157 ,  C12N2533/40 ,  C12N2533/74 ,  G01N33/5088 ,  A61K2300/00 ,  C08L5/04 ,  C08L5/08

    摘要： A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

    摘要翻译： 公开了含有包封哺乳动物细胞和抗炎药物的生物相容性水凝胶的组合物。 包被的细胞在植入受试者后具有减少的纤维化过度生长。 所述组合物包含具有包封哺乳动物细胞和抗炎药物或装有抗炎药物的聚合物颗粒的生物相容性水凝胶。 抗炎药从移植后的组合物中以有效抑制组合物纤维化至少十天的量释放。 还描述了鉴定和选择合适的抗炎药物负载颗粒以防止包封细胞纤维化的方法。 还公开了治疗受试者疾病的方法，其涉及向受试者施用治疗有效量的所公开的封闭细胞。

    HIGH-THROUGHPUT FABRICATION OF MICROPARTICLES
    89.
    发明申请
    HIGH-THROUGHPUT FABRICATION OF MICROPARTICLES 审中-公开
    高通量微波炉的制造

    公开(公告)号：US20110163469A1

    公开(公告)日：2011-07-07

    申请号：US12094098

    申请日：2006-12-13

    申请人： Steven Little ,  Daniel G. Anderson ,  Robert S. Langer

    发明人： Steven Little ,  Daniel G. Anderson ,  Robert S. Langer

    IPC分类号： B29B9/00

    CPC分类号： A61K9/1647 ,  A61K9/1694

    摘要： The high-throughput fabrication of microparticles based on the double emulsion/solvent evaporation technique for screening and optimizing microparticle formulations for particular characteristics allows for the preparation of multiple microparticle formulations in parallel. The system involves the formation of an emulsion containing aqueous bubbles with the payload in an organic phase containing the polymer or polymer blend being used for the microparticles. This first emulsion is then transferred to a larger aqueous phase, and a second waterin-oil-in water emulsion is formed. The organic solvent is then removed, and the resulting particles are optionally washed and/or freeze dried. The resulting microparticles are similar or better than microparticles prepared using the traditional one formulation at a time approach. The high-throughput fabrication of microparticles is particularly useful in optimizing microparticles formulations for drug delivery.

    摘要翻译： 基于用于筛选和优化微粒制剂以获得特定特征的基于双重乳液/溶剂蒸发技术的微粒的高通量制造允许并行制备多个微粒制剂。 该系统包括在含有用于微粒的聚合物或聚合物共混物的有机相中形成含有水泡的含水气泡。 然后将该第一乳液转移到较大的水相中，并形成第二水包油包水乳液。 然后除去有机溶剂，任选地将所得颗粒洗涤和/或冷冻干燥。 所得到的微粒类似于或优于使用传统的一种制剂在一段时间内制备的微粒。 微粒的高通量制造特别可用于优化用于药物递送的微粒制剂。

    ENDOTHELIAL BASEMENT MEMBRANE TARGETING PEPTIDE LIGANDS
    90.
    发明申请
    ENDOTHELIAL BASEMENT MEMBRANE TARGETING PEPTIDE LIGANDS 审中-公开
    内皮基底膜定向肽配体

    公开(公告)号：US20110143993A1

    公开(公告)日：2011-06-16

    申请号：US12969345

    申请日：2010-12-15

    申请人： Robert S. Langer ,  Omid C. Farokhzad ,  Juliana M. Chan

    发明人： Robert S. Langer ,  Omid C. Farokhzad ,  Juliana M. Chan

    IPC分类号： A61K38/08 ,  C07K7/06 ,  A61P35/00 ,  A61P27/02 ,  A61P9/10 ,  A61P7/00 ,  G01N33/68

    CPC分类号： B82Y5/00 ,  A61K38/00 ,  A61K47/59 ,  A61K47/593 ,  A61K47/66 ,  A61K47/6911 ,  A61K47/6935 ,  G01N33/5088 ,  G01N33/6893 ,  G01N2800/00

    摘要： Peptides that selectively bind to antigens exposed in vascular disease or dysfunction have been identified by biopanning a phage library. The ligands are useful when attached to a substrate to be in contact with endothelial surfaces, especially those where drug delivery is utilized, such as following angioplasty, with release from a drug delivery reservoir in a medical device such as a stent, or by administration intravenously in the form of nano or microparticles, although the peptides may also be used with other medical devices or substrates, for targeting or to increase adhesion to endothelial surfaces. The nanoparticle technology can be used to treat injured vasculature, a clinical problem of primary importance. The targeted nanoparticles are also useful in the treatment of other diseases and disorders such as oncologic and regenerative diseases and indications where neoangiogenesis is commonly observed.

    摘要翻译： 已经通过生物淘选噬菌体文库鉴定了选择性结合暴露在血管疾病或功能障碍中的抗原的肽。 当附着于与内皮表面接触的底物时，配体是有用的，特别是那些使用药物递送的那些，例如随后的血管成形术，从医疗装置例如支架中的药物递送储存器释放，或通过静脉内施用 以纳米或微粒的形式，尽管肽也可以与其它医疗装置或底物一起使用，用于靶向或增加对内皮表面的粘附。 纳米颗粒技术可用于治疗受伤的脉管系统，这是一个首要重要的临床问题。 目标纳米颗粒还可用于治疗其他疾病和病症，例如肿瘤和再生疾病和通常观察到血管生成的适应症。